Do pathological parameters differ with regard to breast density and mode of detection in breast cancer? The Malmö Diet and Cancer Study

The Breast ◽  
2015 ◽  
Vol 24 (1) ◽  
pp. 12-17 ◽  
Author(s):  
Hanna Sartor ◽  
Signe Borgquist ◽  
Linda Hartman ◽  
Sophia Zackrisson
Keyword(s):  
Breast Cancer ◽  
Breast Density ◽  
Cancer Study ◽  
Mode Of Detection ◽  
Diet And Cancer

scholarly journals The association of single nucleotide polymorphisms (SNPs) with breast density and breast cancer survival: the Malmö Diet and Cancer Study

2020 ◽  
Vol 61 (10) ◽  
pp. 1326-1334
Author(s):  
Hanna Sartor ◽  
Jasmine Brandt ◽  
Felix Grassmann ◽  
Mikael Eriksson ◽  
Kamila Czene ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Single Nucleotide Polymorphisms ◽  
Breast Density ◽  
Cancer Survival ◽  
Cox Regression ◽  
Breast Cancer Survival ◽  
Nucleotide Polymorphisms ◽  
Single Nucleotide ◽  
Cancer Study ◽  
Diet And Cancer

Background Genetic factors are important in determining breast density, and heritable factors account for 60% of the variation. Certain single nucleotide polymorphisms (SNPs) are associated with density and risk of breast cancer but the association with prognosis is not clear. Purpose To investigate associations between selected SNPs and breast cancer survival in the Malmö Diet and Cancer Study (MDCS). Material and Methods A total of 724 unrelated women with breast cancer and registered radiological and pathological data were identified in MDCS 1991–2007, with genotyping available for 672 women. Associations among 15 SNPs, density, and breast cancer-specific survival were analyzed using logistic/Cox regression, adjusted for factors affecting density and survival. Variants significantly associated with either density or survival were validated in a large independent breast cancer cohort (LIBRO-1). Results Minor homozygotes of SNPs rs9383589, CCDC170 and rs6557161, ESR1 were associated with high breast density (adjusted odds ratio [AOR] 8.97, 95% confidence interval [CI] 1.35–59.57; AOR 2.08, 95% CI 1.19–3.65, respectively) and poorer breast cancer survival (adjusted hazard ratio [HRadj] 6.46, 95% CI 1.95–21.39; HRadj 2.30, 95% CI 1.33–3.96, respectively) compared to major homozygotes. For SNP rs3757318, ESR1, minor homozygotes (HRadj 7.46, 95% CI 2.28–24.45) were associated with poorer survival. We confirmed that rs6557161, ESR1 was significantly associated with both density and survival in the LIBRO-1 study. Conclusion These findings support a shared genetic basis for density and breast cancer survival. The SNP significantly associated with both density and survival in both cohorts may be of interest in future research investigating polygenic risk scores for breast cancer risk and screening stratification purposes.

scholarly journals Statin use, HMGCR expression, and breast cancer survival – The Malmö Diet and Cancer Study

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Olöf Bjarnadottir ◽  
Maria Feldt ◽  
Maria Inasu ◽  
Pär-Ola Bendahl ◽  
Karin Elebro ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Cancer Survival ◽  
Cox Regression ◽  
Histological Grade ◽  
Breast Cancer Patients ◽  
Cancer Study ◽  
Drug Register ◽  
Diet And Cancer ◽  
Statin Use

AbstractStatins, commonly used to treat hypercholesterolemia, have also been proposed as anti-cancer agents. The identification of a predictive marker is essential. The 3-hydroxy-3-methylglutaryl-coenzyme-A reductase (HMGCR), which is inhibited by statins, might serve as such a marker. Thorough antibody validation was performed for four different HMGCR antibodies. Tumor expression of HMGCR (#AMAb90619, CL0260, Atlas Antibodies, Stockholm, Sweden) was evaluated in the Malmö Diet and Cancer Study breast cancer cohort. Statin use and cause of death data were retrieved from the Swedish Prescribed Drug Register and Swedish Death Registry, respectively. Breast cancer-specific mortality (BCM) according to statin use and HMGCR expression were analyzed using Cox regression models. Three-hundred-twelve of 910 breast cancer patients were prescribed statins; 74 patients before and 238 after their breast cancer diagnosis. HMGCR expression was assessable for 656 patients; 119 showed negative, 354 weak, and 184 moderate/strong expressions. HMGCR moderate/strong expression was associated with prognostically adverse tumor characteristics as higher histological grade, high Ki67, and ER negativity. HMGCR expression was not associated with BCM. Neither was statin use associated with BCM in our study. Among breast cancer patients on statins, no or weak HMGCR expression predicted favorable clinical outcome. These suggested associations need further testing in larger cohorts.

scholarly journals Thyroid-associated genetic polymorphisms in relation to breast cancer risk in the Malmö Diet and Cancer Study

2017 ◽  
Vol 142 (7) ◽  
pp. 1309-1321 ◽  
Author(s):  
Jasmine Brandt ◽  
Signe Borgquist ◽  
Peter Almgren ◽  
Asta Försti ◽  
Linnea Huss ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Genetic Polymorphisms ◽  
Cancer Study ◽  
Diet And Cancer

scholarly journals Statin use and patterns of breast cancer recurrence in the Malmö Diet and Cancer Study

The Breast ◽  
2022 ◽  
Author(s):  
Maria Inasu ◽  
Maria Feldt ◽  
Helena Jernström ◽  
Signe Borgquist ◽  
Sixten Harborg
Keyword(s):  
Breast Cancer ◽  
Cancer Recurrence ◽  
Breast Cancer Recurrence ◽  
Cancer Study ◽  
Diet And Cancer ◽  
Statin Use

scholarly journals Breast density and mode of detection in relation to breast cancer specific survival: a cohort study

BMC Cancer ◽  
2014 ◽  
Vol 14 (1) ◽  
Author(s):  
Åsa Olsson ◽  
Hanna Sartor ◽  
Signe Borgquist ◽  
Sophia Zackrisson ◽  
Jonas Manjer
Keyword(s):  
Breast Cancer ◽  
Cohort Study ◽  
Breast Density ◽  
Breast Cancer Specific Survival ◽  
Cancer Specific Survival ◽  
Mode Of Detection

Stable Peptide of the Endogenous Opioid Enkephalin Precursor and Breast Cancer Risk

2015 ◽  
Vol 33 (24) ◽  
pp. 2632-2638 ◽  
Author(s):  
Olle Melander ◽  
Marju Orho-Melander ◽  
Jonas Manjer ◽  
Thomas Svensson ◽  
Peter Almgren ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Middle Aged ◽  
Cancer Study ◽  
Fasting Plasma ◽  
Increased Risk ◽  
Diet And Cancer ◽  
Fourth Quartile ◽  
Incident Breast Cancer

Purpose In experimental studies, enkephalins (ENKs) and related opioids have been implicated as negative regulators of breast cancer development by enhancing immune-mediated tumoral defense as well as directly inhibiting cancer cells. We hypothesized that plasma levels of ENKs are predictive of the long-term breast cancer risk. Therefore, our objective was to measure pro-ENK A, a surrogate for mature ENK, and evaluate its predictive value for the development of breast cancer in a large population of middle-aged women and an independent study population. Patients and Methods We related pro-ENK in fasting plasma samples from 1,929 healthy women (mean age, 57.6 ± 5.9 years) of the Malmö Diet and Cancer study to breast cancer incidence (n = 123) during a median follow-up of 14.7 years. For replication, pro-ENK was related to risk of breast cancer (n = 130) in an older independent sample from the Malmö Preventive Project consisting of 1,569 women (mean age, 70.0 ± 4.4 years). Results In the Malmö Diet and Cancer study, pro-ENK was inversely related to the risk of incident breast cancer, with a hazard ratio per each standard deviation increment of logarithm-transformed pro-ENK of 0.72 (95% CI, 0.62 to 0.85; P < .001). The linear elevation of risk over pro-ENK quartiles 3, 2, and 1, with the fourth quartile as a reference, was 1.38 (95% CI, 0.73 to 2.64), 2.29 (95% CI, 1.26 to 4.15), and 3.16 (95% CI, 1.78 to 5.60; for the trend, P < .001), respectively. These results were replicated in the Malmö Preventive Project, where the continuous odds ratio for incident breast cancer was 0.63 (95% CI, 0.52 to 0.76; P < .001) and the risk over pro-ENK quartiles 3, 2, and 1, where the fourth quartile was the reference, was 2.48 (95% CI, 1.25 to 4.94), 2.94 (95% CI, 1.50 to 5.77), and 4.81 (95% CI, 2.52 to 9.18; for the trend, P < .001), respecitvely. Conclusion Low fasting plasma concentration of the opioid precursor peptide pro-ENK is associated with an increased risk of future breast cancer in middle-aged and postmenopausal women.

Sign in / Sign up

Export Citation Format

Share Document